Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results